From what 6 stock analysts predict, the share price for Regulus Therapeutics Inc (RGLS) might increase by 537.65% in the next year. This is based on a 12-month average estimation for RGLS. Price targets go from $3 to $28. The majority of stock analysts believe RGLS is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Regulus Therapeutics Inc has a total of 6 Wall St Analyst ratings. There are 1 buy ratings, 5 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Regulus Therapeutics Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of RGLS.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Andreas Argyrides Oppenheimer | Outperform | $7 | Reiterates | Aug 14, 2024 |
Raghuram Selvaraju HC Wainwright & Co. | Buy | $10 | Reiterates | Aug 9, 2024 |
Raghuram Selvaraju HC Wainwright & Co. | Buy | $10 | Reiterates | Jul 16, 2024 |
Raghuram Selvaraju HC Wainwright & Co. | Buy | $10 | Maintains | Jun 25, 2024 |
Whitney Ijem Canaccord Genuity | Buy | $28 | Maintains | Jun 25, 2024 |
Catherine Novack Jones Trading | Buy | $8 | Initiates | May 31, 2024 |
Raghuram Selvaraju HC Wainwright & Co. | Buy | $9 | Reiterates | May 10, 2024 |
Raghuram Selvaraju HC Wainwright & Co. | Buy | $9 | Reiterates | May 6, 2024 |
Raghuram Selvaraju HC Wainwright & Co. | Buy | $9 | Reiterates | Mar 25, 2024 |
Whitney Ijem Canaccord Genuity | Buy | $11 | Maintains | Mar 19, 2024 |
Joseph Schwartz Leerink Partners | Outperform | $6 | Initiates | Mar 18, 2024 |
Raghuram Selvaraju HC Wainwright & Co. | Buy | $9 | Reiterates | Mar 18, 2024 |
Jim Birchenough Wells Fargo | Equal-Weight | $3 | Maintains | Mar 13, 2024 |
Raghuram Selvaraju HC Wainwright & Co. | Buy | $9 | Reiterates | Sep 21, 2023 |
Whitney Ijem Canaccord Genuity | Buy | $12 | Maintains | Sep 21, 2023 |
Raghuram Selvaraju HC Wainwright & Co. | Buy | $9 | Reiterates | Sep 19, 2023 |
HC Wainwright & Co. | Buy | Reiterates | Aug 10, 2023 | |
Raghuram Selvaraju HC Wainwright & Co. | Buy | $9 | Reiterates | Jun 28, 2023 |
Raghuram Selvaraju HC Wainwright & Co. | Buy | $9 | Reiterates | Jun 21, 2023 |
Raghuram Selvaraju HC Wainwright & Co. | Buy | $9 | Reiterates | May 15, 2023 |
When did it IPO
2012
Staff Count
31
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Joseph P. Hagan M.B.A.
Market Cap
$104.7M
In 2023, RGLS generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that RGLS's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
No news data available.